BioAtla, Inc. (BCAB)

BioAtla's stock price has experienced significant volatility and a substantial decline over the past six months. Key events include a $40 million SPV transaction with GATC Health in December 2025, the initiation of a strategic options evaluation and restructuring plan in March 2026, the report of a $59.6 million net loss for 2025, and a 50-for-1 reverse stock split in April 2026 to regain Nasdaq compliance.

Information specifically detailing demand seasonality for BioAtla, Inc.'s products and services is not publicly available. Demand for their products, once commercialized, would primarily be driven by disease prevalence, treatment efficacy, regulatory approvals, and market access, rather than typical seasonal consumer patterns.

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancers, operating within the Healthcare sector, specifically in the Biotechnology industry. BioAtla utilizes its proprietary Conditionally Active Biologic (CAB) platform technology to create novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. The company's pipeline includes Mecbotamab vedotin (BA3011), Ozuriftamab vedotin (BA3021), Evalstotug (BA3071), BA3182, BA3361, BA3151, BA3142, BA3311 and BA3241.

BioAtla has operations in San Diego, California, U.S., and in Beijing, China, through a contractual relationship with BioDuro-Sundia. The company's sales are primarily generated in the United States.

BioAtla's brand reputation has likely been negatively impacted by the substantial decline in stock price and the necessity of a reverse stock split. The announcement of strategic options evaluation and workforce reduction also suggests financial challenges. However, FDA alignment on the Phase 3 trial design for Ozuriftamab Vedotin (Oz-V) and promising clinical data for Mecbotamab Vedotin (Mec-V) and BA3182 could bolster scientific and clinical reputation.

BioAtla's ownership is distributed among institutional investors, individual insiders, and retail investors. As of May 7, 2026, institutional ownership is around 22.42%, insider ownership is 30.76%, and retail investors hold 46.82% of the stock. Major institutional owners include Acorn Capital Advisors, Llc, Vanguard Group Inc., Marshall Wace, Llp, Millennium Management Llc, Acadian Asset Management Llc, Renaissance Technologies Llc, Deutsche Bank Ag, Geode Capital Management, Llc, BlackRock, Inc. and Tang Capital Management Llc. Carolyn Anderson Short is the largest individual shareholder, and Jay M. Short, Ph.D., is the CEO and co-founder.